Leukocyte Growth Factor

Neutropenia

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Pegfilgrastim is a covalent conjugate of recombinant methionyl human G-CSF (filgrastim) and monomethoxypolyethylene glycol.  Filgrastim is a water-soluble 175 amino acid protein with a molecular weight of approximately 19 kilodaltons (kD).  Filgrastim is obtained from the bacterial fermentation of a strain of <span class="Italics">E coli</span> transformed with a genetically engineered plasmid containing the human G-CSF gene.  To produce pegfilgrastim, a 20 kD monomethoxypolyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of filgrastim.  The average molecular weight of pegfilgrastim is approximately 39 kD.</p><p>Neulasta is provided in two presentations:</p><ul><li>Neulasta for manual subcutaneous injection is supplied in 0.6 mL prefilled syringes.  The prefilled syringe does not bear graduation marks and is designed to deliver the entire contents of the syringe (6 mg/0.6 mL).</li><li>On-body injector (OBI) for Neulasta is supplied with a prefilled syringe containing 0.64 mL of Neulasta in solution that delivers 0.6 mL of Neulasta in solution when used with the OBI for Neulasta.  The syringe does not bear graduation marks and is only to be used with the OBI for Neulasta.</li></ul><p>The delivered 0.6 mL dose from either the prefilled syringe for manual subcutaneous injection or the OBI for Neulasta contains 6 mg pegfilgrastim (based on protein weight) in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), polysorbate 20 (0.02 mg), sodium (0.02 mg), and sorbitol (30 mg) in Water for Injection, USP.</p></section>

Neulasta

0.6 ML pegfilgrastim 10 MG/ML Injection

0.6 ML pegfilgrastim 10 MG/ML Injection [Neulasta]

pegfilgrastim

0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe

0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe [Neulasta]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Reimbursement Information

Billing & Coding - Hospital Outpatient 

Billing & Coding Guide - Physician Office 

Benefit Verification & PA Form 

Amgen SupportPlus Enrollment Form 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity

Enroll in Patient Savings Program 

Injector Disposal Program 

Other HCP Resources 

Patient Stories 

About Neulasta 

Side Effects 

Patient Resources 

Doctor Discussion Guide 

TSA Card for Neulasta 

FAQs - Risk Reduction of Febrile Neutropenia Post Chemotherapy

Patient Brochure 

Instructions For Use: Single-Use On-Body Injector

Instructions For Use: Single-Dose Prefilled Syringe